Duality Advisers, LP Ascendis Pharma A/S Transaction History

Duality Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 02, 2023	BUY	$86.5 - $103.97 $397,467 - $477,742	4,595 Added 75.48%	10,683 $1 Million
Q2 2023 Jul 31, 2023	BUY	$69.96 - $97.84 $425,916 - $595,649	6,088 New	6,088 $543,000
Q1 2022 May 09, 2022	SELL	$102.18 - $135.75 $258,106 - $342,904	-2,526 Closed	0 $0
Q4 2021 Feb 02, 2022	BUY	$127.1 - $169.66 $321,054 - $428,561	2,526 New	2,526 $340,000
Q3 2021 Nov 08, 2021	SELL	$112.67 - $176.92 $612,812 - $962,267	-5,439 Closed	0 $0
Q2 2021 Aug 09, 2021	SELL	$121.62 - $145.29 $481,007 - $574,621	-3,955 Reduced 42.1%	5,439 $716,000
Q1 2021 May 13, 2021	BUY	$124.92 - $173.33 $785,247 - $1.09 Million	6,286 Added 202.25%	9,394 $1.21 Million
Q4 2020 Feb 09, 2021	BUY	$151.2 - $182.76 $469,929 - $568,018	3,108 New	3,108 $518,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.